aPKC inhibitors might be the sensitizer of chemotherapy and adoptive immunotherapy in the treatment of hASIPa - Overexpressed breast cancer

	aPKC inhibitors might be the sensitizer of chemotherapy and adoptive immunotherapy in the treatment of hASIPa - Overexpressed breast cancer
	Jin, YT; Ying, XX; Hu, YH; Zou, Q; Wang, HY; Xu, YH
刊名	ONCOLOGY RESEARCH
	2008
卷号	17 期号:2 页码:59-68
关键词	human breast cancer hASIP aPKC inhibitor 5-FU DCIK/DCIK-P cells
通讯作者	Zou, Q (reprint author), Fudan Univ, Shanghai Med Sch, Huashan Hosp, Dept Surg, Shanghai 200040, Peoples R China.,zouqiang003@yahoo.com.cn
英文摘要	The atypical protein kinase C (aPKC) plays an important role in cell growth through the interaction with its substracts, including human ASIP (hASIP), which contains an aPKC phosphorylation site encoded by exon 17b of the gene. hASIP is expressed as numerous alternative splicing isoforms in the cells. Our results showed that hASIPa, an exon 17b-containing isoform of hASIP, is overexpressed in human breast cancer (HBC) MDA-MB-231, SK-BR-3, and MCF-7 cell lines and HBC specimens. The anticancer effects of 5-FU chemotherapy or adoptive immunotherapy and the synergic action of aPKC inhibitor against hASIPa-overexpressed HBC cells were tested. The results indicated that HBC MDA-MB-231 and SK-BR-3 cells were sensitive to 5-FU treatment in vitro. The combined treatment of aPKC inhibitor and 5-FU raised the anticancer activities against hASIPa-overexpressed HBC cells. The coculture of cytokine-induced killer (CIK) cells and autologous dendritic cells (DCs) with or without Her-2 peptide GP2 pulse created two new populations of effective immune-active T-cell populations called DC-modulated and cytokine-induced killer (DCIK) cells and peptide-DC-modulated and cytokine-induced killer (DCIK-P) cells. The DCIK cells showed cytotoxic activities on MDA-MB-231, SK-BR-3, and MCF-7 cells in MHC unrestricted manner. The DCIK-P cells possessed extra-enhanced cytotoxic activities against HLA-A2+/Her-2+ MDA-MB-231 cells in MHC restricted manner, but not for HLA-A2 +/-/Her-2+ SK-BR-3 cells and HLA-A2+Her-2 +/- MCF-7 cells. The data suggested specific cytotoxic T-lymphocyte (CTL) activity of DCIK-P cells on MDA-MB-231 cells. The combined treatment of aPKC inhibitor with DCIK/DCIK-P cells further raised the anticancer activities against hASIPa-overexpressed HBC cells. The results demonstrated that the hASIPa/aPKC signaling pathway functions as an important regulator in the growth of HBC cells and aPKC inhibitor treatment showed the synergic activities on 5-FU or DCIK/DCIK-P cells adoptive immunotherapy against hASIPa-overexpressed HBC cells.
学科主题	Oncology
类目[WOS]	Oncology
关键词[WOS]	INDUCED KILLER-CELLS ; KINASE-C-IOTA ; TRANSCRIPTION FACTOR ; DENDRITIC CELLS ; LUNG-CANCER ; PROTEIN ; POLARITY ; ISOFORMS ; SPECIFICITY ; EXPRESSION
收录类别	SCI
语种	英语
WOS记录号	WOS:000255969900002
内容类型	期刊论文
版本	出版稿
源URL	[http://202.127.25.143/handle/331003/1350]
专题	上海生化细胞研究所_上海生科院生化细胞研究所
推荐引用方式 GB/T 7714	Jin, YT,Ying, XX,Hu, YH,et al. aPKC inhibitors might be the sensitizer of chemotherapy and adoptive immunotherapy in the treatment of hASIPa - Overexpressed breast cancer[J]. ONCOLOGY RESEARCH,2008,17(2):59-68.
APA	Jin, YT,Ying, XX,Hu, YH,Zou, Q,Wang, HY,&Xu, YH.(2008).aPKC inhibitors might be the sensitizer of chemotherapy and adoptive immunotherapy in the treatment of hASIPa - Overexpressed breast cancer.ONCOLOGY RESEARCH,17(2),59-68.
MLA	Jin, YT,et al."aPKC inhibitors might be the sensitizer of chemotherapy and adoptive immunotherapy in the treatment of hASIPa - Overexpressed breast cancer".ONCOLOGY RESEARCH 17.2(2008):59-68.